Abbott Laboratories Current Ratio 2010-2025 | ABT
Current and historical current ratio for Abbott Laboratories (ABT) from 2010 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Abbott Laboratories current ratio for the three months ending March 31, 2025 was 1.78.
| Abbott Laboratories Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-03-31 | $23.15B | $13.00B | 1.78 |
| 2024-12-31 | $23.66B | $14.16B | 1.67 |
| 2024-09-30 | $23.80B | $14.90B | 1.60 |
| 2024-06-30 | $23.12B | $13.76B | 1.68 |
| 2024-03-31 | $22.38B | $14.02B | 1.60 |
| 2023-12-31 | $22.67B | $13.84B | 1.64 |
| 2023-09-30 | $22.66B | $13.04B | 1.74 |
| 2023-06-30 | $23.51B | $14.35B | 1.64 |
| 2023-03-31 | $24.38B | $14.53B | 1.68 |
| 2022-12-31 | $25.22B | $15.49B | 1.63 |
| 2022-09-30 | $24.85B | $13.37B | 1.86 |
| 2022-06-30 | $24.96B | $12.39B | 2.01 |
| 2022-03-31 | $23.43B | $12.65B | 1.85 |
| 2021-12-31 | $24.24B | $13.11B | 1.85 |
| 2021-09-30 | $23.49B | $12.87B | 1.83 |
| 2021-06-30 | $22.63B | $12.61B | 1.79 |
| 2021-03-31 | $21.82B | $12.46B | 1.75 |
| 2020-12-31 | $20.44B | $11.91B | 1.72 |
| 2020-09-30 | $17.39B | $10.26B | 1.70 |
| 2020-06-30 | $17.22B | $10.96B | 1.57 |
| 2020-03-31 | $15.50B | $10.81B | 1.43 |
| 2019-12-31 | $15.67B | $10.86B | 1.44 |
| 2019-09-30 | $16.12B | $10.49B | 1.54 |
| 2019-06-30 | $15.20B | $9.06B | 1.68 |
| 2019-03-31 | $14.41B | $9.11B | 1.58 |
| 2018-12-31 | $14.63B | $9.01B | 1.62 |
| 2018-09-30 | $18.20B | $12.78B | 1.42 |
| 2018-06-30 | $14.12B | $8.95B | 1.58 |
| 2018-03-31 | $14.96B | $9.01B | 1.66 |
| 2017-12-31 | $20.15B | $8.91B | 2.26 |
| 2017-09-30 | $21.38B | $7.94B | 2.69 |
| 2017-06-30 | $19.98B | $6.80B | 2.94 |
| 2017-03-31 | $19.33B | $6.65B | 2.91 |
| 2016-12-31 | $26.78B | $6.66B | 4.02 |
| 2016-09-30 | $12.98B | $8.32B | 1.56 |
| 2016-06-30 | $12.99B | $8.67B | 1.50 |
| 2016-03-31 | $12.41B | $8.39B | 1.48 |
| 2015-12-31 | $14.16B | $9.19B | 1.54 |
| 2015-09-30 | $15.89B | $8.76B | 1.82 |
| 2015-06-30 | $21.13B | $9.19B | 2.30 |
| 2015-03-31 | $19.99B | $9.21B | 2.17 |
| 2014-12-31 | $13.56B | $10.47B | 1.30 |
| 2014-09-30 | $16.46B | $10.82B | 1.52 |
| 2014-06-30 | $18.26B | $9.85B | 1.85 |
| 2014-03-31 | $17.93B | $10.19B | 1.76 |
| 2013-12-31 | $19.25B | $9.51B | 2.03 |
| 2013-09-30 | $19.75B | $11.33B | 1.74 |
| 2013-06-30 | $19.83B | $10.92B | 1.82 |
| 2013-03-31 | $19.10B | $10.41B | 1.84 |
| 2012-12-31 | $31.32B | $13.28B | 2.36 |
| 2012-09-30 | $27.26B | $16.29B | 1.67 |
| 2012-06-30 | $26.26B | $17.12B | 1.53 |
| 2012-03-31 | $25.60B | $16.79B | 1.53 |
| 2011-12-31 | $23.77B | $15.48B | 1.54 |
| 2011-09-30 | $23.09B | $15.41B | 1.50 |
| 2011-06-30 | $24.13B | $15.84B | 1.52 |
| 2011-03-31 | $23.65B | $17.23B | 1.37 |
| 2010-12-31 | $22.32B | $17.26B | 1.29 |
| 2010-09-30 | $19.45B | $15.58B | 1.25 |
| 2010-06-30 | $19.92B | $14.69B | 1.36 |
| 2010-03-31 | $17.69B | $15.18B | 1.17 |
| 2009-12-31 | $23.31B | $13.05B | 1.79 |
| 2009-09-30 | $21.42B | $12.53B | 1.71 |
| 2009-06-30 | $19.63B | $12.04B | 1.63 |
| 2009-03-31 | $18.01B | $11.77B | 1.53 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $229.206B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $152.664B | 38.22 |
| Stryker (SYK) | United States | $149.191B | 31.19 |
| EssilorLuxottica (ESLOY) | France | $131.913B | 0.00 |
| Medtronic (MDT) | Ireland | $115.147B | 16.32 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.094B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.531B | 24.85 |
| ResMed (RMD) | United States | $37.280B | 28.00 |
| GE HealthCare Technologies (GEHC) | United States | $34.547B | 16.40 |
| Agilent Technologies (A) | United States | $32.221B | 21.01 |
| Terumo (TRUMY) | Japan | $24.355B | 31.64 |
| Koninklijke Philips (PHG) | Netherlands | $23.476B | 16.47 |
| Insulet (PODD) | United States | $20.287B | 79.63 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.641B | 11.97 |
| Baxter (BAX) | United States | $14.559B | 10.87 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.951B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.729B | 23.42 |
| Lantheus Holdings (LNTH) | United States | $5.148B | 12.99 |
| Perrigo (PRGO) | Ireland | $3.724B | 9.44 |
| Prestige Consumer Healthcare (PBH) | United States | $3.715B | 16.59 |
| Haemonetics (HAE) | United States | $3.575B | 16.28 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.342B | 27.77 |
| ICU Medical (ICUI) | United States | $3.072B | 22.66 |
| LeMaitre Vascular (LMAT) | United States | $1.867B | 41.72 |
| QuidelOrtho (QDEL) | United States | $1.864B | 12.82 |
| AtriCure (ATRC) | United States | $1.504B | 0.00 |
| Acuren (TIC) | United States | $1.431B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.238B | 15.82 |
| AdaptHealth (AHCO) | United States | $1.232B | 12.51 |
| Green Thumb Industries (GTBIF) | United States | $1.212B | 27.26 |
| Neogen (NEOG) | United States | $1.068B | 13.67 |
| BioLife Solutions (BLFS) | United States | $1.006B | 0.00 |
| InMode (INMD) | Israel | $0.901B | 9.08 |
| Kestra Medical Technologies (KMTS) | United States | $0.788B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.642B | 0.00 |
| Owens & Minor (OMI) | United States | $0.613B | 5.08 |
| Tilray Brands (TLRY) | Canada | $0.607B | 0.00 |
| Evolus (EOLS) | United States | $0.593B | 0.00 |
| CeriBell (CBLL) | United States | $0.571B | 0.00 |
| Valneva SE (VALN) | France | $0.552B | 0.00 |
| Surmodics (SRDX) | United States | $0.446B | 0.00 |
| SNDL (SNDL) | Canada | $0.392B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.331B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.321B | 11.82 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.300B | 0.00 |
| Quanterix (QTRX) | United States | $0.283B | 0.00 |
| Cerus (CERS) | United States | $0.270B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.264B | 22.30 |
| Cresco Labs (CRLBF) | United States | $0.260B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.67 |
| Sanara MedTech (SMTI) | United States | $0.248B | 0.00 |
| ZimVie (ZIMV) | United States | $0.243B | 11.04 |
| OraSure Technologies (OSUR) | United States | $0.239B | 0.00 |
| Brainsway (BWAY) | Israel | $0.230B | 60.75 |
| Biote (BTMD) | United States | $0.224B | 6.31 |
| Omeros (OMER) | United States | $0.206B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.202B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.200B | 0.00 |
| High Tide (HITI) | Canada | $0.197B | 0.00 |
| Organigram Global (OGI) | Canada | $0.196B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 14.87 |
| TriSalus Life Sciences (TLSI) | United States | $0.178B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.152B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.16 |
| TerrAscend (TSNDF) | Canada | $0.101B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.100B | 12.87 |
| MacroGenics (MGNX) | United States | $0.096B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.090B | 0.00 |
| Veru (VERU) | United States | $0.088B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.086B | 0.00 |
| Apyx Medical (APYX) | United States | $0.079B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.075B | 0.00 |
| Zynex (ZYXI) | United States | $0.069B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.068B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| United-Guardian (UG) | United States | $0.043B | 14.76 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.037B | 49.29 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.022B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |